{
  "entity_id": "B-001022",
  "folder": "Life-Saving-Drugs-Program-Expert-Panel",
  "name": "Life Saving Drugs Program Expert Panel",
  "type": "Advisory Body",
  "jurisdiction": "Commonwealth",
  "portfolio": "Health, Disability and Ageing",
  "website": "https://www.health.gov.au/committees-and-groups/life-saving-drugs-program-expert-panel",
  "data_status": "partial",
  "completeness": {
    "has_strategy_brief": false,
    "has_strategy_structured": true,
    "has_vision": false,
    "has_kpi_targets": false,
    "has_kpi_results": false,
    "has_strategy_overview": true,
    "has_legislation_text": true,
    "has_legislation_structured": false,
    "has_global_initiatives_text": false,
    "has_global_initiatives_structured": false,
    "n_global_initiatives": 0,
    "has_ideas": true,
    "has_artifacts": true,
    "n_ideas": 12,
    "n_legislation": 0,
    "n_artifacts": 2,
    "n_kpi_targets": 0,
    "n_kpi_results": 0,
    "n_outcomes": 0,
    "verified_own_data": true
  },
  "strategy_profile": {
    "status": "needs_review",
    "confidence": "medium",
    "summary": "",
    "official_site_url": "https://www.health.gov.au/committees-and-groups/life-saving-drugs-program-expert-panel",
    "source_documents": [
      {
        "type": "strategie",
        "title": "Standard for AI transparency statements",
        "url": "https://www.digital.gov.au/sites/default/files/documents/2024-08/Standard%20for%20AI%20transparency%20statements%20v1.1.pdf",
        "period": "2024",
        "confidence": "medium"
      }
    ],
    "purpose": null,
    "vision": null,
    "strategic_priorities": [],
    "values": [],
    "outcomes": [],
    "performance_measures": [],
    "document_alignment_terms": {
      "must_support": [],
      "watch_terms": [],
      "avoid_claiming_without_evidence": []
    },
    "review_note": "Structured strategy exists but is incomplete."
  },
  "global_initiatives": null,
  "strategy": {
    "reporting_period": "2024-25",
    "corporate_plan_period": "2025-26",
    "vision": null,
    "vision_source_page": null,
    "purposes": null,
    "purposes_source_page": null,
    "how_we_deliver": null,
    "how_we_deliver_source_page": null,
    "government_priorities": [],
    "outcomes": [],
    "values": [],
    "values_framework_name": null,
    "kpi_targets_2025_26": [],
    "kpi_results_2024_25": [],
    "_source_urls": {
      "annual_report_url": "",
      "corporate_plan_url": ""
    }
  },
  "ideas": [
    {
      "entity_id": "B-001022",
      "entity_name": "Life Saving Drugs Program Expert Panel",
      "folder_name": "Life-Saving-Drugs-Program-Expert-Panel",
      "category": "Citizen Services",
      "scale": "small",
      "title": "Plain-language service pages and proactive status updates",
      "idea": "Rewrite high-volume pages and letters into plain language, add status notifications, and measure contact reduction.",
      "quote": "[Page 2]\nStandard for AI transparency statements\nDigital Transformation Agency\n© Commonwealth of Australia (Digital Transformation Agency) 2024 | Version 1801\nWith the exception of the Commonwealth Coat of Arms and where otherwise noted, this\nproduct is provided under a Creative Commons Attribution 4.0 International Licence.\n(http://creativecommons.org/licenses/by/4.0/legalcode)\nThe Digital Transformation Agency has tried to make the information in this product\nas accurate as possible.",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "Citizens / service users",
      "source": "strategies/Standard-20for-20AI-20transparency-20statements-20v1.1.pdf (https://www.digital.gov.au/sites/default/files/documents/2024-08/Standard%20for%20AI%20transparency%20statements%20v1.1.pdf)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Digital exclusion",
        "Low public trust if feedback is not acted on"
      ]
    },
    {
      "entity_id": "B-001022",
      "entity_name": "Life Saving Drugs Program Expert Panel",
      "folder_name": "Life-Saving-Drugs-Program-Expert-Panel",
      "category": "Citizen Services",
      "scale": "large",
      "title": "Single front door for life-event based services",
      "idea": "Bundle services around life events so citizens can complete related steps across agencies in one journey.",
      "quote": "[Page 2]\nStandard for AI transparency statements\nDigital Transformation Agency\n© Commonwealth of Australia (Digital Transformation Agency) 2024 | Version 1801\nWith the exception of the Commonwealth Coat of Arms and where otherwise noted, this\nproduct is provided under a Creative Commons Attribution 4.0 International Licence.\n(http://creativecommons.org/licenses/by/4.0/legalcode)\nThe Digital Transformation Agency has tried to make the information in this product\nas accurate as possible.",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Citizens / service users",
      "source": "strategies/Standard-20for-20AI-20transparency-20statements-20v1.1.pdf (https://www.digital.gov.au/sites/default/files/documents/2024-08/Standard%20for%20AI%20transparency%20statements%20v1.1.pdf)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Digital exclusion",
        "Low public trust if feedback is not acted on"
      ]
    },
    {
      "entity_id": "B-001022",
      "entity_name": "Life Saving Drugs Program Expert Panel",
      "folder_name": "Life-Saving-Drugs-Program-Expert-Panel",
      "category": "Data & Performance",
      "scale": "small",
      "title": "KPI evidence register with named owners",
      "idea": "Create a simple register mapping each KPI to source data, owner, frequency, target, and last result.",
      "quote": "This could include (but should not be limited to) uncertainty around:\n• Treatment guidelines (including eligibility criteria, dosage amount and frequency)\n• Life extension/survival benefit\n• Clinical effectiveness in terms of surrogate outcomes\n• Medicine safety\n• Reliability of diagnostic test\n• Extent of use\n• Patient relevant outcomes\nA proposal for managing uncertainty should include:\n• Proposed price of the medicine\n• Areas of uncertainty\n• Timeframe for evidence collection\n• Pre-determined pricing consequences of updated evidence gathered (if required)\nIn its review of the application, the LSDP Expert Panel will provide advice about sources of\nuncertainty based on issues identified in the application and the proposals from the sponsor\nto address, and make recommendations about how these can be addressed through further\ndata collection.",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "Executives / Parliament / public",
      "source": "other-pdfs/procedure-guidance-for-medicines-funded-through-the-life-saving-drugs-program-ls.pdf (https://www.health.gov.au/sites/default/files/documents/2021/11/procedure-guidance-for-medicines-funded-through-the-life-saving-drugs-program-lsdp.pdf)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability"
      ]
    },
    {
      "entity_id": "B-001022",
      "entity_name": "Life Saving Drugs Program Expert Panel",
      "folder_name": "Life-Saving-Drugs-Program-Expert-Panel",
      "category": "Data & Performance",
      "scale": "large",
      "title": "Outcome dashboard linking budget, delivery, and public impact",
      "idea": "Build a public-facing outcome dashboard showing spend, outputs, outcomes, and delivery confidence.",
      "quote": "This could include (but should not be limited to) uncertainty around:\n• Treatment guidelines (including eligibility criteria, dosage amount and frequency)\n• Life extension/survival benefit\n• Clinical effectiveness in terms of surrogate outcomes\n• Medicine safety\n• Reliability of diagnostic test\n• Extent of use\n• Patient relevant outcomes\nA proposal for managing uncertainty should include:\n• Proposed price of the medicine\n• Areas of uncertainty\n• Timeframe for evidence collection\n• Pre-determined pricing consequences of updated evidence gathered (if required)\nIn its review of the application, the LSDP Expert Panel will provide advice about sources of\nuncertainty based on issues identified in the application and the proposals from the sponsor\nto address, and make recommendations about how these can be addressed through further\ndata collection.",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Executives / Parliament / public",
      "source": "other-pdfs/procedure-guidance-for-medicines-funded-through-the-life-saving-drugs-program-ls.pdf (https://www.health.gov.au/sites/default/files/documents/2021/11/procedure-guidance-for-medicines-funded-through-the-life-saving-drugs-program-lsdp.pdf)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability"
      ]
    },
    {
      "entity_id": "B-001022",
      "entity_name": "Life Saving Drugs Program Expert Panel",
      "folder_name": "Life-Saving-Drugs-Program-Expert-Panel",
      "category": "Staff Productivity",
      "scale": "small",
      "title": "Reusable briefing and summary assistant for internal documents",
      "idea": "Create controlled templates for summarising reports, submissions, minutes, and ministerial briefs.",
      "quote": "We have made Copilot Chat available to all staff and are rolling out Microsoft 365 Copilot licenced version to staff in phases.",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "APS staff / executives",
      "source": "pages/announcements-index.html (https://www.health.gov.au/about-us/corporate-reporting/our-commitments/ai-transparency-statement)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Sensitive information leakage",
        "Inconsistent quality of generated drafts"
      ]
    },
    {
      "entity_id": "B-001022",
      "entity_name": "Life Saving Drugs Program Expert Panel",
      "folder_name": "Life-Saving-Drugs-Program-Expert-Panel",
      "category": "Staff Productivity",
      "scale": "large",
      "title": "Department-wide knowledge and briefing platform",
      "idea": "Build a secure knowledge platform that lets staff search, summarise, and cite approved departmental material.",
      "quote": "We have made Copilot Chat available to all staff and are rolling out Microsoft 365 Copilot licenced version to staff in phases.",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "APS staff / executives",
      "source": "pages/announcements-index.html (https://www.health.gov.au/about-us/corporate-reporting/our-commitments/ai-transparency-statement)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Sensitive information leakage",
        "Inconsistent quality of generated drafts"
      ]
    },
    {
      "entity_id": "B-001022",
      "entity_name": "Life Saving Drugs Program Expert Panel",
      "folder_name": "Life-Saving-Drugs-Program-Expert-Panel",
      "category": "Regulation & Policy",
      "scale": "small",
      "title": "Regulatory burden scan for forms, guidance, and reporting",
      "idea": "Identify the top 10 highest-friction reporting obligations and simplify guidance, forms, or evidence requirements.",
      "quote": "In continuing to comply with the Framework and 10 National Principles, while leveraging the outcome of our annual risk assessment, our key initiatives include:\nimproving staff awareness of the department’s Child Safety Policy and their obligations under the policy\nour senior executive continuing to support and promote the application of the Child Safety Policy across our department\nensuring child safe clauses are included in grants or procurement documents for funded third parties where required\nensuring relevant staff complete required training and get and/or maintain relevant checks where required.",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "Regulated entities / policy teams",
      "source": "pages/announcements-index__04.html (https://www.health.gov.au/topics/about-the-department/corporate-reporting/our-commitments/child-safety)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Regulatory capture",
        "Over-automation of judgement"
      ]
    },
    {
      "entity_id": "B-001022",
      "entity_name": "Life Saving Drugs Program Expert Panel",
      "folder_name": "Life-Saving-Drugs-Program-Expert-Panel",
      "category": "Regulation & Policy",
      "scale": "large",
      "title": "Adaptive regulation program with live feedback loops",
      "idea": "Create an adaptive regulation model using sandboxes, industry data, risk scoring, and regular rule updates.",
      "quote": "In continuing to comply with the Framework and 10 National Principles, while leveraging the outcome of our annual risk assessment, our key initiatives include:\nimproving staff awareness of the department’s Child Safety Policy and their obligations under the policy\nour senior executive continuing to support and promote the application of the Child Safety Policy across our department\nensuring child safe clauses are included in grants or procurement documents for funded third parties where required\nensuring relevant staff complete required training and get and/or maintain relevant checks where required.",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Regulated entities / policy teams",
      "source": "pages/announcements-index__04.html (https://www.health.gov.au/topics/about-the-department/corporate-reporting/our-commitments/child-safety)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Regulatory capture",
        "Over-automation of judgement"
      ]
    },
    {
      "entity_id": "B-001022",
      "entity_name": "Life Saving Drugs Program Expert Panel",
      "folder_name": "Life-Saving-Drugs-Program-Expert-Panel",
      "category": "Risk & Assurance",
      "scale": "small",
      "title": "Recommendation tracker for audits, reviews, and inquiries",
      "idea": "Publish a single internal tracker for audit/review recommendations, owners, due dates, and implementation evidence.",
      "quote": "During the 2024-25 financial year, we acted to further strengthen our compliance with the\nCommonwealth Child Safe Framework\nand to minimise key risks, including:\nreviewing and updating the Department's Child Safety Policy, with additional guidance about risk management and working with children check requirements for all Australian jurisdictions\nproviding additional guidance information about child safety risks for departmental staff undertaking annual risk assessment processes\nmaturity self-assessment to identify areas for improvement aligned to annual risk assessment processes\nOur divisional business and risk planning process includes an annual risk assessment regarding the level of direct or indirect contact with children across our department.",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "Executives / assurance teams",
      "source": "pages/announcements-index__04.html (https://www.health.gov.au/topics/about-the-department/corporate-reporting/our-commitments/child-safety)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Regulatory capture",
        "Over-automation of judgement"
      ]
    },
    {
      "entity_id": "B-001022",
      "entity_name": "Life Saving Drugs Program Expert Panel",
      "folder_name": "Life-Saving-Drugs-Program-Expert-Panel",
      "category": "Risk & Assurance",
      "scale": "large",
      "title": "Integrated assurance and lessons-learned system",
      "idea": "Create an assurance system that connects audit findings, risk registers, delivery reviews, and investment decisions.",
      "quote": "During the 2024-25 financial year, we acted to further strengthen our compliance with the\nCommonwealth Child Safe Framework\nand to minimise key risks, including:\nreviewing and updating the Department's Child Safety Policy, with additional guidance about risk management and working with children check requirements for all Australian jurisdictions\nproviding additional guidance information about child safety risks for departmental staff undertaking annual risk assessment processes\nmaturity self-assessment to identify areas for improvement aligned to annual risk assessment processes\nOur divisional business and risk planning process includes an annual risk assessment regarding the level of direct or indirect contact with children across our department.",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Executives / assurance teams",
      "source": "pages/announcements-index__04.html (https://www.health.gov.au/topics/about-the-department/corporate-reporting/our-commitments/child-safety)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Regulatory capture",
        "Over-automation of judgement"
      ]
    },
    {
      "entity_id": "B-001022",
      "entity_name": "Life Saving Drugs Program Expert Panel",
      "folder_name": "Life-Saving-Drugs-Program-Expert-Panel",
      "category": "Case Processing",
      "scale": "small",
      "title": "Triage queue for stuck or ageing cases",
      "idea": "Use existing case data to flag ageing, duplicate, incomplete, or high-risk cases for earlier intervention.",
      "quote": "During the 2024-25 financial year, we acted to further strengthen our compliance with the\nCommonwealth Child Safe Framework\nand to minimise key risks, including:\nreviewing and updating the Department's Child Safety Policy, with additional guidance about risk management and working with children check requirements for all Australian jurisdictions\nproviding additional guidance information about child safety risks for departmental staff undertaking annual risk assessment processes\nmaturity self-assessment to identify areas for improvement aligned to annual risk assessment processes\nOur divisional business and risk planning process includes an annual risk assessment regarding the level of direct or indirect contact with children across our department.",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "Applicants / case officers",
      "source": "pages/announcements-index__04.html (https://www.health.gov.au/topics/about-the-department/corporate-reporting/our-commitments/child-safety)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability"
      ]
    },
    {
      "entity_id": "B-001022",
      "entity_name": "Life Saving Drugs Program Expert Panel",
      "folder_name": "Life-Saving-Drugs-Program-Expert-Panel",
      "category": "Case Processing",
      "scale": "large",
      "title": "End-to-end case processing redesign",
      "idea": "Redesign the case pathway around risk-based triage, reusable evidence, and automated eligibility checks.",
      "quote": "During the 2024-25 financial year, we acted to further strengthen our compliance with the\nCommonwealth Child Safe Framework\nand to minimise key risks, including:\nreviewing and updating the Department's Child Safety Policy, with additional guidance about risk management and working with children check requirements for all Australian jurisdictions\nproviding additional guidance information about child safety risks for departmental staff undertaking annual risk assessment processes\nmaturity self-assessment to identify areas for improvement aligned to annual risk assessment processes\nOur divisional business and risk planning process includes an annual risk assessment regarding the level of direct or indirect contact with children across our department.",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Applicants / case officers",
      "source": "pages/announcements-index__04.html (https://www.health.gov.au/topics/about-the-department/corporate-reporting/our-commitments/child-safety)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability"
      ]
    }
  ],
  "legislation_administered": [],
  "artifacts": [
    {
      "category": "strategies",
      "year": "2024",
      "url": "https://www.digital.gov.au/sites/default/files/documents/2024-08/Standard%20for%20AI%20transparency%20statements%20v1.1.pdf",
      "file": "strategies/Standard-20for-20AI-20transparency-20statements-20v1.1.pdf",
      "bytes": 289017,
      "link_text": "Standard for AI transparency statements"
    },
    {
      "category": "other-pdfs",
      "year": "2021",
      "url": "https://www.health.gov.au/sites/default/files/documents/2021/11/procedure-guidance-for-medicines-funded-through-the-life-saving-drugs-program-lsdp.pdf",
      "file": "other-pdfs/procedure-guidance-for-medicines-funded-through-the-life-saving-drugs-program-ls.pdf",
      "bytes": 687889,
      "link_text": "Procedure guidance for medicines funded through the Life Saving Drugs Program (LSDP) [PDF - 672 KB] - 30 pages"
    }
  ],
  "_meta": {
    "snapshot_built_at": "2026-05-14T02:13:08+00:00",
    "strategy_brief_meta": {
      "model": "nova-micro",
      "folder": "Life-Saving-Drugs-Program-Expert-Panel",
      "annual_report": {
        "file": null,
        "url": "",
        "year": null
      },
      "corporate_plan": {
        "file": "strategies\\Standard-20for-20AI-20transparency-20statements-20v1.1.txt",
        "url": "https://www.digital.gov.au/sites/default/files/documents/2024-08/Standard%20for%20AI%20transparency%20statements%20v1.1.pdf",
        "year": null
      },
      "usage": {
        "input_tokens": 2799,
        "output_tokens": 155,
        "total_tokens": 2954,
        "model": "nova-micro"
      },
      "cost_usd": 0.000119665,
      "elapsed_seconds": 4.76,
      "generated_at": "2026-05-13T05:17:27+00:00"
    },
    "ideas_manifest": {
      "entity_id": "B-001022",
      "entity_name": "Life Saving Drugs Program Expert Panel",
      "folder_name": "Life-Saving-Drugs-Program-Expert-Panel",
      "generated_at": "2026-05-09T23:05:36.649805+00:00",
      "idea_count": 12,
      "markdown": "ideas/Life-Saving-Drugs-Program-Expert-Panel_ideas.md",
      "jsonl": "ideas/ideas.jsonl",
      "inputs": [
        "Life-Saving-Drugs-Program-Expert-Panel_strategy-overview.md",
        "strategy-evidence.json",
        "global-intelligence/source-manifest.json"
      ]
    },
    "global_intel_meta": null
  }
}